A new review published in Climacteric in October 2026 lays out the biological case for why women in perimenopause and menopause so often need metabolic support beyond lifestyle changes alone. And it is one of the clearest explanations I have seen in the literature for something I see in my practice every single day.
What Estrogen Loss Actually Does to Your Metabolism
Most women going through perimenopause know their hormones are changing. What most are never told is how profoundly estrogen loss reshapes their metabolism, entirely independent of diet, exercise, or anything else they are doing.
Estrogen plays a central role in appetite regulation, insulin sensitivity, and how the body stores fat. As estrogen declines, fat storage shifts from the hips and thighs to the abdomen. And that abdominal fat is not passive. It is metabolically active tissue that secretes fatty acids and pro-inflammatory mediators, driving chronic low-grade inflammation, insulin resistance, and cardiometabolic dysfunction. At the same time, the loss of estrogen directly impairs glucose and lipid regulation, worsening insulin resistance and pushing triglycerides and LDL in the wrong direction.
The cumulative result is an accelerating risk for sarcopenia, dyslipidemia, type 2 diabetes, and cardiovascular disease. This is not aging. This is the specific and well-documented metabolic consequence of estrogen loss, and most women are never given that explanation.
The GLP-1 Connection
Glucagon-like peptide-1 receptor agonists, the class of medications that includes semaglutide and tirzepatide, work by regulating appetite, slowing gastric emptying, improving insulin secretion, and reducing glucagon. They directly address several of the metabolic consequences that estrogen loss creates.
What makes this paper particularly interesting is that it reviews preclinical evidence of a biological interaction between estrogen and GLP-1 signaling pathways. Estradiol has been shown to increase GLP-1 secretion from intestinal and pancreatic cells. These two systems are not independent. They interact. And this helps explain why women on both hormone therapy and a GLP-1 lose more weight than women on a GLP-1 alone, a finding that has now appeared across multiple studies.
Beyond weight, GLP-1 receptor agonists in this population have demonstrated improvements in cardiovascular outcomes, liver fat, blood pressure, and cholesterol. These are not weight loss drugs. They are metabolic health drugs. That framing matters enormously for how we talk about them with patients.
What We Do Not Know Yet
The authors of this paper are appropriately honest about the gaps, and I think clinicians should be too. We do not yet have large, well-designed randomized trials specifically in perimenopausal and postmenopausal women. Most of the data on combined hormone therapy and GLP-1 use comes from small observational studies that cannot establish causality. Long-term data on bone health, skeletal muscle mass, and menopause-specific quality of life outcomes with these medications remains limited. The authors are calling for that research, and it cannot come soon enough.
How I Approach This in Practice
The foundation comes first, always. Sleep, stress management, strength training, and adequate protein intake are non-negotiable. These are the things that protect muscle mass, support metabolic function, and make every other intervention work better. No medication replaces them.
Then hormones. Getting estrogen optimized addresses the root driver of the metabolic dysfunction. I call it leveling the playing field. For many women, this alone makes a significant difference in how their body responds to diet and exercise.
For some women, I also consider metformin, even without a diabetes diagnosis. In women who are hyperinsulinemic, metformin has shown meaningful and sustained improvements in insulin resistance and weight when combined with dietary changes. It is a tool that is underused in this population and worth discussing.
And when more is needed on top of that, GLP-1 receptor agonists are where the strongest evidence sits. Not as a shortcut. Not as a last resort. As part of a comprehensive, layered approach in women whose metabolic burden has outpaced what hormones and lifestyle alone can address.
The Bottom Line
If you are in perimenopause or menopause, doing everything right, and still struggling, the biology in this paper helps explain why. The metabolic changes of this transition are real, they are significant, and they are not your fault. Treating them with the full range of tools available is not giving up. It is meeting the problem with the response it deserves.
Foundation first. Hormones next. And when you need more, we have the tools.
Reference - Erkan IBO, Senturk LM, Erel CT, Seyisoglu HH, Sahmay S, Durmusoglu F. GLP-1 receptor agonists in perimenopause and early postmenopause: clinical role, cardiometabolic benefits and knowledge gaps. Climacteric. Published online October 8, 2026. doi:10.1080/13697137.2026.2735765